A bipolar disorder question should be answered from the current episode, not the diagnosis alone. Acute mania, bipolar depression, relapse prevention and possible medicine toxicity require different decisions. Before choosing a treatment, establish what has changed, what the person is already taking, what has previously helped and whether the immediate priority is psychiatric, physical or both.
This guide concerns adult UK practice and MRCPsych Paper B learning. Clinical recommendations were checked on 27 September 2026 against NICE CG185, current MHRA valproate advice and NHS medicines-monitoring guidance. The paired cases are fictional educational exercises, not official examination questions or individual treatment plans.
Establish the current episode and immediate priorities
Begin with the longitudinal account. Describe the change in sleep, energy, activity, mood, thought speed, judgement and functioning relative to the person's usual state. Ask whether the person feels rested despite substantially less sleep, rather than treating every episode of insomnia as evidence of mania. Clarify duration and the effect on relationships, spending, work, self-care and safety.
A diagnosis of bipolar disorder does not make every new symptom an affective episode. Physical illness, substances, medicines, sleep disruption and coexisting psychiatric conditions may alter the presentation. An abrupt change with disorientation or new neurological findings should not be explained away by the psychiatric history. NICE's assessment recommendations support a full history, differential assessment and consideration of physical and psychosocial factors.
In a written question, identify the requested action. "Most appropriate next assessment" is not the same as "long-term prophylaxis". A clinically reasonable maintenance medicine can still be the wrong answer when urgent assessment of dehydration, toxicity or immediate risk is required first.
Differentiate mania, hypomania and competing causes
Do not use a single symptom as a diagnostic shortcut. Elevated or irritable mood becomes clinically meaningful through the associated pattern, time course, change from baseline and consequences. Impaired judgement, marked disruption or psychotic features change the severity assessment; the word "energetic" by itself establishes little.
The history should distinguish a new episodic change from a longstanding pattern. Lifelong distractibility may prompt a neurodevelopmental assessment, while a distinct period of reduced sleep and markedly altered behaviour raises a different question. Those possibilities can coexist. A substance exposure also requires interpretation of timing rather than automatic dismissal of the underlying mood disorder.
A useful original decision table is:
| Current problem | Information that changes the answer | Tempting but incomplete shortcut |
|---|---|---|
| Possible acute mania | Severity, current medicines, previous response, physical state and immediate safety | Choose any drug described as a mood stabiliser |
| Bipolar depression | Prior manic or hypomanic episodes, current treatment and clinical urgency | Apply a generic unipolar-depression prescription |
| Stable interval between episodes | Previous episode pattern, benefits, adverse effects, preferences and monitoring feasibility | Continue every acute medicine indefinitely without review |
| New tremor, vomiting or confusion during lithium treatment | Current symptoms, hydration, renal function, sampling context and interacting medicines | Assume the old lithium result excludes toxicity |
The table organises the task; it is not a replacement diagnostic or prescribing algorithm.
Work through an acute management choice
NICE CG185, checked on 27 September 2026, advises considering stopping an antidepressant when mania or hypomania develops during antidepressant monotherapy and offering an appropriate antipsychotic. Its listed options include haloperidol, olanzapine, quetiapine and risperidone, selected in light of the person's preferences, previous response and clinical context. It specifically advises against using lamotrigine to treat mania. NICE recommendations on mania.
That does not make the options interchangeable. A history of severe adverse effects, physical comorbidity or a previous effective treatment can change the defensible choice. State the factor that matters rather than inventing a universal ranking of antipsychotics.
For someone already taking a maintenance medicine, assess adherence, exposure and monitoring before reflexively adding another treatment. A low reported concentration may reflect missed treatment, sampling circumstances or a change in elimination; a result should be interpreted with the clinical situation. SPS guidance on lithium safety, checked on 27 September 2026, emphasises treating the person rather than the number alone.
Severe disturbance may also require a different level of care, support with hydration and self-care, or an urgent assessment of safety and capacity. Those practical decisions should not disappear merely because the question contains a familiar medicine name.
Approach bipolar depression as a separate decision
Bipolar depression is not simply mania with the opposite mood, and the acute-mania treatment sequence should not be copied unchanged. NICE's options for moderate or severe bipolar depression include quetiapine alone or fluoxetine combined with olanzapine in the relevant untreated setting, with alternatives and adjustments according to existing therapy and patient preference. Someone already taking lithium requires review of that treatment and its level before choosing the next addition. NICE CG185, section 1.6, checked on 27 September 2026.
The learning task is to recognise which branch the person occupies. "Fluoxetine is mentioned in bipolar depression guidance" does not mean that unsupported antidepressant monotherapy is the same recommendation. Likewise, a treatment that may have a role in bipolar depression does not automatically have a role in acute mania.
Psychological treatment, physical health, social circumstances and the person's priorities remain part of the plan. An examination answer should preserve the distinction between selecting a medicine and constructing care around a person who may be struggling with work, relationships, self-neglect or suicidal thoughts.
Plan maintenance and relapse prevention
After an acute episode, revisit the longer-term strategy rather than leaving the temporary crisis plan untouched. Record which symptoms improved, what adverse effects occurred and what the person considers a worthwhile outcome. NICE recommends lithium as a first-line long-term pharmacological option, with treatment selection informed by previous benefit, suitability and preferences. It also recommends structured psychological interventions designed for bipolar disorder. NICE CG185, section 1.7.
A useful relapse-prevention plan is specific. It identifies the person's early changes, who may notice them, what the person wishes others to do, who to contact and how the plan will be reviewed. "Watch for relapse" is less useful than recording the patient's own recognisable pattern and agreed response.
Monitoring should have an owner. A medicine appearing on several records does not establish which service checks results, contacts the patient after an abnormal finding or reviews a new interaction. The SPS lithium-safety guidance highlights the importance of communication across the prescribing and monitoring system.
Review lithium and valproate safety in context
For lithium, new vomiting, coarse tremor, ataxia, confusion or other concerning symptoms require assessment for toxicity. A concentration within a previously accepted range does not exclude a current problem. SPS advises withholding lithium, obtaining urgent relevant blood tests and seeking specialist advice when toxicity is suspected; urgency depends on the presentation. SPS lithium monitoring, checked on 27 September 2026.
Routine care also considers renal and thyroid function, calcium, interactions, hydration and the circumstances of level sampling. Distinguish a planned review of long-term tolerability from an acutely unwell patient who needs immediate assessment. A revision card that only remembers the target concentration misses that distinction.
Valproate requires an explicitly dated regulatory check. The MHRA's February 2025 clarification, checked on 27 September 2026, retains the two-specialist requirement for initiation in patients younger than 55 but does not require that same review solely because a male patient is already taking it. Current materials also retain important requirements for women and girls who could become pregnant. A generic "avoid in pregnancy" note is not a complete account of the prescribing safeguards.
The MHRA additionally describes precautionary reproductive advice for male patients, including contraception during treatment and for three months after stopping. It acknowledges uncertainty about causality in the underlying paternal-exposure evidence. Patients should not stop treatment abruptly on their own; planning a family warrants specialist discussion. MHRA reproductive-risk information, checked on 27 September 2026.
Four paired case variants
Each pair changes a fact that should alter the reasoning. All details are invented for education.
Pair one: low mood versus a new activated episode
In variant A, an adult has persistent low mood and reduced function, with a clear past manic episode but no current activation. The question concerns bipolar depression, so use the depression branch and review existing treatment.
In variant B, the same person develops markedly reduced need for sleep, escalating activity and impaired judgement after starting antidepressant monotherapy. The task now includes possible mania and review of the antidepressant, not simply intensifying depression treatment. The discriminating information is the new episode pattern, not the fact that the original complaint was low mood.
A poor explanation says only "the diagnosis changed". A stronger one describes the observed change and why it selects a different management branch under NICE CG185.
Pair two: a missed regimen versus possible toxicity
Variant A describes a patient on lithium whose relapse follows a confirmed period of missed treatment, without physical symptoms suggesting toxicity. Clarify adherence and the circumstances of the measured level, then agree a supervised management plan.
Variant B adds vomiting, unsteadiness, reduced intake and deteriorating renal function. Now urgent assessment for lithium toxicity takes priority. The same word "relapse" in a referral should not obscure a new medical problem, and an old satisfactory level does not answer the current question. SPS lithium monitoring supports the safety distinction.
Pair three: one medicine, different episode
Variant A concerns a patient with bipolar depression in whom lamotrigine is being considered within an appropriate specialist treatment discussion. The learner should examine the relevant depression or maintenance context, including prior treatment and safety information.
Variant B changes the presentation to acute mania and proposes lamotrigine as the immediate treatment. That substitution is not supported by NICE's mania recommendations. The exercise tests whether the learner knows the indication in context rather than merely recognising a medicine associated with bipolar disorder.
Pair four: new valproate initiation versus an established male patient
Variant A concerns proposed first initiation of valproate in a man younger than 55. The current initiation safeguards and specialist documentation need to be addressed before treating it as an ordinary next prescription.
Variant B concerns an established male patient of the same age who is considering parenthood. The task is not to invent a retrospective initiation requirement or abruptly stop a successful treatment. It is to provide the current precautionary advice and arrange specialist review of options. The MHRA's clarification distinguishes these situations.
Explain why the alternative is wrong
For each missed question, write four short entries: the current episode, the feature that selected the branch, the safety constraint and the reason the tempting alternative failed. This is more informative than copying a complete treatment list.
A wrong answer may reflect failure to recognise the episode, failure to check current therapy, use of an outdated regulatory rule or failure to recognise acute physical deterioration. Those are different learning needs. Per iatroX's September 2026 specification, question-linked Socratic tutoring can probe that particular misconception before another unaided attempt. It does not replace medicine-specific guidance or a specialist plan for a real patient.
Frequently asked questions
Is every medicine called a mood stabiliser appropriate for acute mania?
No. Match the medicine to the episode and current guidance; NICE specifically advises against using lamotrigine to treat mania.
Can a previous normal lithium level rule out current toxicity?
No. New symptoms and changes in renal function, hydration or interactions require a fresh clinical assessment and appropriately timed investigation.
Are valproate safeguards identical for initiation and established male treatment?
No. The MHRA distinguishes new initiation in patients younger than 55 from men already taking valproate, while reproductive counselling and appropriate specialist review remain important.